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Caveolin-1The Na+-coupled glucose transporter SGLT1 (SLC5A1) accomplishes concentrative cellular glucose uptake
even at low extracellular glucose concentrations. The carrier is expressed in renal proximal tubules, small in-
testine and a variety of nonpolarized cells including several tumor cells. The present study explored whether
SGLT1 activity is regulated by caveolin-1, which is known to regulate the insertion of several ion channels and
carriers in the cell membrane. To this end, SGLT1 was expressed in Xenopus oocytes with or without additional
expression of caveolin-1 and electrogenic glucose transport determined by dual electrode voltage clamp exper-
iments. In SGLT1-expressing oocytes, but not in oocytes injected with water or caveolin-1 alone, the addition of
glucose to the extracellular bath generated an inward current (Ig), which was increased following coexpression
of caveolin-1. Kinetic analysis revealed that caveolin-1 increased maximal Ig without signiﬁcantly modifying the
glucose concentration required to trigger half maximal Ig (KM). According to chemiluminescence and confocal
microscopy, caveolin-1 increased SGLT1 protein abundance in the cell membrane. Inhibition of SGLT1 insertion
by brefeldin A (5 μM) resulted in a decline of Ig, which was similar in the absence and presence of caveolin-1. In
conclusion, caveolin-1 up-regulates SGLT1 activity by increasing carrier protein abundance in the cellmembrane,
an effect presumably due to stimulation of carrier protein insertion into the cell membrane.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Caveolins are the major components of caveolae, cholesterol and
glycosphingolipid-rich invaginations of the plasma membrane [1]. Those
membrane domains may participate in the clustering of channels and
carriers [2]. Caveolins may thus participate in the regulation of channel
abundance in the cell membrane, channel activity and thus channel de-
pendent functions such as cell volume regulation [2–4]. Caveolin dysfunc-
tion may participate in the pathophysiology of diverse clinical disorders,
such as atherosclerosis, inﬂammatory bowel disease,muscular dystrophy,
lipodystrophies, dyslipidaemia and cardiac arrhythmia [3,5–7]. Caveolins
are implicated in the regulation of transmembrane transport of nutrients
including glucose [8]. Compelling evidence suggests the participation of
caveolins in the regulation of renal tubular transport [9].
Speciﬁcally, caveolin-1 could participate in the regulation of the
Na+-coupled glucose carrier SGLT1 [10], which is primarily expressed
in epithelial cells and accomplishes the concentrative cellular uptake of
glucose from the lumen across the apical cell membrane [11]. SGLT1 is,
in addition, expressed in several tumor cells [12–19],whichutilizemainlyiversity of Tübingen, Gmelinstr.
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l rights reserved.glucose as fuel [14]. In contrast to facilitative glucose transport by carriers
from the GLUT family, Na+-coupled glucose transport could accumulate
glucose against a concentration gradient, i.e. at extracellular glucose con-
centrations far below the intracellular glucose concentrations [11].
Mechanisms regulating SGLT1 include the EGF receptor, which
interacts with and stabilizes SGLT1 [13,19]. SGLT1 has been shown
to be upregulated by the HPV18 E6 protein from human papilloma
virus [20], the causative agent of severalmalignancies [21–23].Moreover,
SGLT1 is regulated by several kinases including protein kinase A (PKA)
[24,25], protein kinase C (PKC) [24,25], serum- and glucocorticoid-
inducible kinase [26], AMP-activated kinase [27], Janus kinase 2 [28]
and Tau tubulin kinase TTBK2 [29].
The present study explored the putative regulation of SGLT1 by
caveolin-1. To this end, SGLT1 was expressed in Xenopus oocytes with
or without additional coexpression of caveolin-1 and the electrogenic
glucose transport determined utilizing dual electrode voltage clamp.2. Materials and methods
2.1. Constructs
For the generation of cRNA, constructs were used encoding human
wild-type SGLT1 (SLC5A1) [26] and human wild-type caveolin-1
(Imagenes GmbH, Berlin, Germany).
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Xenopus oocytes were prepared as previously described [30].
Unless stated otherwise, 10 ng of cRNA encoding wild type human
caveolin-1 and 10 ng cRNA encoding SGLT1 were injected on the
same day of preparation of the oocytes. Oocytes were maintained at
17 °C in ND96-A solution containing 88.5 mM NaCl, 2 mM KCl,
1.8 mM CaC12, 1 mM MgC12, 5 mM HEPES, 0.11 mM tretracycline,
4 μM ciproﬂoxacin, 0.22 mM gentamycin (Refobacin©), 0.5 mM
theophylline (Euphylong©) as well as 5 mM sodium pyruvate. The
pH was adjusted to 7.4 by adding NaOH. Oocytes were superfused
continuously with a solution containing 96 mM NaCl, 2 mM KCl,
1.8 mM CaCl2, 1 mM MgCl2 and 5 mM HEPES (pH = 7.4). Pipettes
were ﬁlled with 3 M KCl and had resistances of 0.5–1.0 MΩ [31,32].
Where indicated, brefeldin A (5 μM, Sigma, Schnelldorf, Germany)
was added. Glucose was added to the solutions at a concentration of
2 mM unless otherwise stated. The ﬂow rate of the superfusion was
approx. 20 ml/min, and a complete exchange of the bath solution
was reached within about 10 s [33]. The voltage clamp experiments
were performed at room temperature 3 days after injection. Two-
electrode voltage-clamp recordings were performed at a holding
potential of −70 mV. The data were ﬁltered at 10 Hz and recorded
with a Digidata 1322A A/D–D/A converter and Clampex V.4.02 soft-
ware for data acquisition and analysis (Axon Instruments, Union
City, CA, USA). The data were analyzed with Clampﬁt V. 9.0.1.07 soft-
ware (Axon Instruments) [34].
2.3. Detection of SGLT1 cell surface expression by chemiluminescence
Defolliculated oocytes were incubated with rabbit polyclonal
anti-SGLT1 antibody (diluted 1:1000, Millipore, Billerica, MA, USA)
and subsequently with secondary goat anti-rabbit HRP-conjugated
antibody (1:1000, Cell Signaling Technology,MA, USA). Post-staining in-
dividual oocytes were placed in 96 well plates with 20 μl of SuperSignal
ELISA Femto Maximum Sensitivity Substrate (Pierce, Rockford, IL, USA)
and chemiluminescence of single oocytes was quantiﬁed in a lumi-
nometer (Walter Wallac 2 plate reader, Perkin Elmer, Juegesheim,
Germany) by integrating the signal over a period of 1 s. Results display
normalized relative light units [35].
2.4. Immunocytochemistry and confocal microscopy
Oocytes were ﬁxed in 4% paraformaldehyde at room temperature
for at least 4 h. After washing with phosphate buffered saline (PBS),
the oocytes were permeabilized and blocked at room temperature
for 1 h in TBS containing 0.1% Triton X-100 and 10% normal goat
serum. Then, the oocyteswere incubated overnight at 4 °Cwith primary
rabbit polyclonal anti-SGLT1 antibody (diluted 1:1000, Millipore, USA)
followed by 1 h incubation at room temperature with FITC-goat
anti-rabbit IgG (diluted 1:1000, Invitrogen, Molecular Probes, Eugene,
OR, USA). The oocytes were analyzed by a ﬂuorescence laser scanning
microscope (LSM 510, Zeiss, Germany) with A-Plan 10×/0.25. Bright-
ness and contrast settings were kept constant during imaging of all
oocytes in each injection series. The ﬂuorescence intensity reﬂecting
SGLT1 membrane abundance was quantiﬁed by ZEN 2009 software
(Carl Zeiss MicroImaging).
2.5. Statistical analysis
Data are provided as means ± SEM, n represents the number of
oocytes investigated. All experiments were repeated with at least 3
batches of oocytes and in all repetitions qualitatively similar data
were obtained. Data were tested for signiﬁcance using ANOVA or
t-test, as appropriate. Results with p b 0.05 were considered statisti-
cally signiﬁcant.3. Results
In order to elucidate whether caveolin-1 inﬂuences the function
of SGLT1, cRNA encoding SGLT1 was injected into Xenopus oocytes
with or without additional injection of cRNA encoding caveolin-1.
Electrogenic glucose transport was estimated from the glucose
induced inward current (Ig) utilizing dual electrode voltage clamp
(TEVC). Following addition of 2 mM glucose, no appreciable Ig was
observed in water-injected Xenopus oocytes or in Xenopus oocytes
expressing caveolin-1 alone, indicating that Xenopus oocytes do not
express appreciable electrogenic glucose transport (Fig. 1). In contrast,
addition of 2 mM glucose generated a large Ig in Xenopus oocytes
expressing SGLT1 (SLC5A1). The additional expression of caveolin-1
was followed by a signiﬁcant increase of Ig in SGLT1-expressing Xenopus
oocytes (Fig. 1A, B).
A further series of experiments explored whether the effect of
caveolin-1 depended on the amount of cRNA injected. As shown in
Fig. 1C, coexpression of SGLT1 with different amounts of caveolin-1
(2 ng, 5 ng, 10 ng and 20 ng) was followed by an upregulation of
the glucose-induced inward current (Ig), reaching statistical signiﬁ-
cance at 10 ng caveolin-1 cRNA.
Additional experiments were performed utilizing glucose concen-
trations ranging from 1 μM to 5 mM in order to elucidate whether
caveolin-1 affected SGLT1 activity by modifying maximal transport
rate or afﬁnity of the carrier (Fig. 2). Kinetic analysis of the glucose-
induced currents in SGLT1-expressing Xenopus oocytes yielded a maxi-
mal current of 79.5 ± 10.6 nA (n = 8). Coexpression of caveolin-1 sig-
niﬁcantly (p b 0.05) enhanced themaximal current to 116.9 ± 12.5 nA
(n = 10). Calculation of the glucose concentration required for half
maximal current (KM) yielded values of 645 ± 111 μM (n = 8) in
oocytes expressing SGLT1 alone and of 504 ± 116 μM (n = 7–12) in
oocytes expressing both, SGLT1 and caveolin-1, values not signiﬁcantly
different. Thus, coexpression of caveolin-1 enhanced SGLT1 activity at
least in part by increasing the maximal current.
The increased maximal electrogenic glucose transport in SGLT1-
expressing Xenopus oocytes following coexpression of caveolin-1 could
have resulted from increased carrier protein abundance in the plasma
membrane. Thus, confocal microscopy and chemiluminescence experi-
ments were employed in order to determine the SGLT1 protein abun-
dance in the cell membrane of Xenopus oocytes injected with water or
expressing either SGLT1 alone or together with caveolin-1. As shown
in Fig. 3, the coexpression of caveolin-1 was followed by a signiﬁcant
increase of SGLT1 protein abundance within the oocyte cell membrane.
Caveolin-1 could enhance SGLT1 protein abundance either by
stimulating carrier protein insertion into the cell membrane or by
delaying retrieval of carrier protein from the cell membrane. In order
to discriminate between those two possibilities the SGLT1-expressing
Xenopus oocytes were treated with 5 μM brefeldin A, which disrupts
the insertion of new carrier protein into the cellmembrane. As illustrated
in Fig. 4, the glucose induced current declined in the presence of
brefeldin A at a similar rate in oocytes expressing SGLT1 alone and in
oocytes expressing SGLT1 togetherwith caveolin-1. After 24 h treatment
with brefeldin A, Ig was similarly decreased in oocytes expressing SGLT1
together with caveolin-1 as in oocytes expressing SGLT1 alone. Thus,
caveolin-1 did not delay the retrieval of SGLT1 protein from the cell
membrane but rather up-regulated SGLT1 by stimulating carrier inser-
tion into the cell membrane.
4. Discussion
The present study demonstrates that coexpression of caveolin-1
increased SGLT1 protein abundance in the cell membrane and thus
enhanced electrogenic glucose uptake into SGLT1-expressing Xenopus
oocytes. Accordingly, caveolin-1 increased the maximal transport rate
of the carrier. Caveolin-1 coexpression did not signiﬁcantly modify
the glucose concentration required for half saturation of the carrier
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Fig. 1. Effect of caveolin-1 coexpression on electrogenic glucose transport in SGLT1-expressing Xenopus oocytes. A: Representative original tracings showing glucose (2 mM)-induced
current (Ig) in Xenopus oocytes injected with water (a), expressing caveolin-1 alone (b), expressing SGLT1 without (c) or with (d) additional coexpression of caveolin-1. B: Arithmetic
means ± SEM (n = 27–39) of glucose (2 mM)-induced current (Ig) in Xenopus oocytes injected with water (ﬁrst dotted bar) or expressing caveolin-1 alone (second dotted bar), ex-
pressing SGLT1 alone (white bar), or expressing SGLT1 togetherwith caveolin-1 (black bar). *** indicates statistically signiﬁcant (p b 0.001) difference from Xenopus oocytes expressing
SGLT1 alone. ### indicates statistically signiﬁcant (p b 0.001) difference from Xenopus oocytes without SGLT1 expression. C: Arithmetic means ± SEM (n = 11–16) of glucose
(2 mM)-induced current (Ig) in Xenopus oocytes injected with water (dotted bar), expressing SGLT1 alone (white bar), or expressing SGLT1 together with 2 ng (1st black bar), 5 ng
(2nd black bar), 10 ng (3rd black bar) or 20 ng (4th black bar) of caveolin-1 cRNA. * indicates statistically signiﬁcant (p b 0.05) difference from Xenopus oocytes expressing SGLT1 alone.
2396 B. Elvira et al. / Biochimica et Biophysica Acta 1828 (2013) 2394–2398(apparent KM). The scatter of the data does, however, not rule out
some minor inﬂuence of caveolin-1 on substrate afﬁnity of SGLT1.
SGLT1 accomplishes cellular glucose uptake across the brush border
of small intestine and proximal renal tubules [11]. Moreover, SGLT1 is
expressed in a variety of tumor cells [12–19]. The uphill glucose trans-
port into the cell is driven by Na+ entry down its electrochemical
gradient across the plasma membrane. Tumor cells may further take
up glucose by facilitative glucose transporter GLUT1 [36,37], a carrier,
however, unable to establish glucose gradients across the cell mem-
brane and thus possibly not sufﬁcient at low extracellular glucoseI G
lu
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Fig. 2. Effect of caveolin-1 coexpression on maximal electrogenic glucose transport in
SGLT1-expressing Xenopus oocytes. Arithmetic means ± SEM (n = 4–12) of glucose
induced current (Ig) as a function of glucose concentration in Xenopus oocytes expressing
SLC5A1 (SGLT1) alone (white circles) or together with caveolin-1 (black circles).concentrations [14]. Unlike the passive GLUT carriers, the Na+-coupled
secondary glucose uptake requires ATP-consuming extrusion of the
cotransported Na+ by the Na+/K+ ATPase [38]. Thus, the carrier indi-
rectly consumes energy.
SGLT1 protein is integrated into caveolae and is thus clustered
in lipid rafts [10]. It is tempting to speculate that the clustering of
SGLT1 with carrier regulating kinases fosters the interaction of the
kinases with the carrier and thus supports kinase dependent regula-
tion of the carrier.
Caveolae are well known to participate in the regulation of the
facilitative glucose carriers [39] and may similarly regulate the
Na+-coupled glucose carrier SGLT1 [10]. Caveolin may be effective
by inﬂuencing carrier regulating kinases [39,40] and may participate
in the regulation of carrier protein trafﬁcking and sorting [41–43].
Caveolae are particularly decisive in the regulation of glucose trans-
port by insulin [39]. The insulin receptor directly interacts with
caveolin, thus directing the protein to caveolae [43]. As a matter of
fact, insulin has been shown to regulate SGLT1 activity [44]. In proxi-
mal renal tubules, caveolin-1 participates in the up-regulation of SGLT
by cAMP sensitive protein kinase A (PKA) [10]. The effect of PKA
on SGLT translocation required intact ﬁlamentous actin (F-actin)
[10]. According to the present study (Fig. 4), caveolin-1 increases the
protein abundance in the cell membrane by fostering insertion of
channels into rather than delaying clearance of channel protein from
the cell membrane.
In conclusion, caveolin-1 up-regulates the Na+-coupled glucose
transporter SGLT1 and may integrate the carrier together with its reg-
ulating kinases in lipid rafts of both, epithelial and nonpolarized cells.
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Fig. 3. Effect of caveolin-1 coexpression on SGLT1 protein abundance in the Xenopus oocyte cell membrane. A: Confocal images of protein abundance in the plasma membrane
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alone (white bar), or expressing SGLT1 together with caveolin-1 (black bar). ** indicates statistically signiﬁcant (p b 0.01) difference from Xenopus oocytes expressing SGLT1 alone.
C: Arithmetic means ± SEM (n = 134–163) of SGLT1 protein abundance determined by chemiluminescence in Xenopus oocytes injected with water (dotted bar), expressing SGLT1
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Fig. 4. Effects of brefeldin A on electrogenic glucose transport in Xenopus oocytes expressing SGLT1 alone or together with caveolin-1. Arithmetic means ± SEM (n = 5–14) of
glucose (2 mM)-induced current (Ig) in Xenopus oocytes expressing SGLT1 without (white bars) and with (black bars) caveolin-1 in the absence (left bars) or presence of 5 μM
brefeldin A for 24 h (middle bars) or 48 h (right bars) prior to the measurements. *** indicates statistically signiﬁcant (p b 0.001) difference from Xenopus oocytes expressing
SGLT1 alone. ### indicates statistically signiﬁcant (p b 0.001) difference from the absence of brefeldin A.
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